TY - JOUR
T1 - A Research and Development (R&D) roadmap for influenza vaccines
T2 - Looking toward the future
AU - The Influenza Vaccines R&D Roadmap Taskforce
AU - Moore, Kristine A.
AU - Ostrowsky, Julia T.
AU - Kraigsley, Alison M.
AU - Mehr, Angela J.
AU - Bresee, Joseph S.
AU - Friede, Martin H.
AU - Gellin, Bruce G.
AU - Golding, Josephine P.
AU - Hart, Peter J.
AU - Moen, Ann
AU - Weller, Charlotte L.
AU - Osterholm, Michael T.
AU - Ampofo, William
AU - Barclay, Wendy
AU - Cavaleri, Marco
AU - Cohen, Cheryl
AU - Cowling, Benjamin
AU - Cox, Rebecca
AU - Gust, Ian
AU - Innis, Bruce
AU - Kang, Gagandeep
AU - Katz, Jacqueline
AU - Krammer, Florian
AU - Pitisuttithum, Punnee
AU - Post, Diane
AU - Rudenko, Larisa
AU - Siqueira, Marilda
AU - Weir, Jerry
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/10/29
Y1 - 2021/10/29
N2 - Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.
AB - Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.
KW - Broadly protective influenza vaccines
KW - Influenza
KW - Pandemic preparedness
KW - Roadmap
KW - Seasonal influenza vaccines
KW - Universal influenza vaccines
UR - http://www.scopus.com/inward/record.url?scp=85117200775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117200775&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2021.08.010
DO - 10.1016/j.vaccine.2021.08.010
M3 - Review article
C2 - 34602302
AN - SCOPUS:85117200775
SN - 0264-410X
VL - 39
SP - 6573
EP - 6584
JO - Vaccine
JF - Vaccine
IS - 45
ER -